Clinical Trials Browser

Phase 1/2 × Antibodies, Monoclonal × 90 days × Clear all

NCT04262466 2026-03-06

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Phase 1/2 Active not recruiting

Other solid neoplasm

Select Advanced Solid Tumors

NCT06840119 2026-01-28

Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers

Phase 1/2 Recruiting

Neoplasms